Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 15/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404345 | 0.88 | KIF11 (0.72) | KIF11ABCG2LMNATP53ABCB1 | |
| SCHEMBL8404344 | 0.84 | KIF11 (0.81) | KIF11ABCG2LMNATP53ABCB1 | |
| SCHEMBL8402610 | 0.83 | KIF11 (0.72) | KIF11ABCG2LMNATP53ABCB1 | |
| SCHEMBL9961948 | 0.83 | KIF11 (0.72) | KIF11ABCG2LMNATP53ABCB1 | |
| SCHEMBL1120736 | 0.80 | KIF11 (0.77) | KIF11ABCG2LMNATP53 | |
| SCHEMBL3564179 | 0.80 | KIF11 (1.00) | KIF11LMNA | |
| SCHEMBL16299589 | 0.80 | KIF11 (0.69) | KIF11ABCG2LMNATP53ABCB1 | |
| SCHEMBL763487 | 0.78 | KIF11 (0.51) | KIF11ABCG2LMNATP53ABCB1 | |
| SCHEMBL9961949 | 0.77 | KIF11 (0.63) | KIF11ABCG2LMNATP53MAPT | |
| SCHEMBL9961950 | 0.77 | KIF11 (0.63) | KIF11ABCG2LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | VEGFA, FLT4, FLT1 | KIF11 2890/4885ABCG2 3386/4885LMNA 2964/4885 |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, PGF | KIF11 3253/4885ABCG2 3580/4885LMNA 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.